Trial Outcomes & Findings for Surgical Trial Comparing LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Stand (NCT NCT01549925)

NCT ID: NCT01549925

Last Updated: 2016-01-28

Results Overview

To evaluate whether the use of the LIGASURE surgical device during omentectomy and/or recto-sigmoid resection for women with ovarian cancer will reduce the surgical time compared to standard surgical resection using clamps and surgical ligatures

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

50 participants

Primary outcome timeframe

at time of surgery, up to 10 minutes

Results posted on

2016-01-28

Participant Flow

Participant milestones

Participant milestones
Measure
Standard Surgical Resection
standard surgical resection using clamps and surgical ligatures Standard Surgical resection: standard surgical resection using clamps and surgical ligatures
LIGASURE
Resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon LIGASURE: resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
Overall Study
STARTED
25
25
Overall Study
COMPLETED
25
25
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Surgical Trial Comparing LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Stand

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Standard Surgical Resection
n=25 Participants
standard surgical resection using clamps and surgical ligatures Standard Surgical resection: standard surgical resection using clamps and surgical ligatures
LIGASURE
n=25 Participants
Resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon LIGASURE: resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
Total
n=50 Participants
Total of all reporting groups
Age, Customized
< 50 years
1 Participants
n=5 Participants
7 Participants
n=7 Participants
8 Participants
n=5 Participants
Age, Customized
50-70 years
16 Participants
n=5 Participants
13 Participants
n=7 Participants
29 Participants
n=5 Participants
Age, Customized
>70 years
8 Participants
n=5 Participants
5 Participants
n=7 Participants
13 Participants
n=5 Participants
Sex: Female, Male
Female
25 Participants
n=5 Participants
25 Participants
n=7 Participants
50 Participants
n=5 Participants
Sex: Female, Male
Male
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants

PRIMARY outcome

Timeframe: at time of surgery, up to 10 minutes

To evaluate whether the use of the LIGASURE surgical device during omentectomy and/or recto-sigmoid resection for women with ovarian cancer will reduce the surgical time compared to standard surgical resection using clamps and surgical ligatures

Outcome measures

Outcome measures
Measure
Standard Surgical Resection
n=25 Participants
standard surgical resection using clamps and surgical ligatures Standard Surgical resection: standard surgical resection using clamps and surgical ligatures
LIGASURE
n=25 Participants
Resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon LIGASURE: resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
Surgical Time
417 SECONDS
Interval 378.0 to 455.0
338 SECONDS
Interval 296.0 to 379.0

Adverse Events

Standard Surgical Resection

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

LIGASURE

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Mark Wade

Huntsman Cancer Institute

Phone: 801-213-5746

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place